Cell Health Sciences
Pharmaceutical manufacturer / contract manufacturer · Islamabad · Pakistan
Islamabad pharmaceutical manufacturer represented in current DRAP product records and contract-manufacturing activity.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Pharmaceutical manufacturer / contract manufacturer
- Address
- Plot No. 217, Industrial Triangle, Kahuta Road, Islamabad, Pakistan
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 50%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Burip Bupropione HCl : ;Source observed | — | 75 mg | Tablet | 1x10's | 136751Official source ↗ | No indexed price | — | — |
| Cellzee | Anastrozole | 1 mg | Tablet | 30's | 093375 | PKR 11,248.03 | PKR 374.93/tablet | 10% above median |
| Cellzol | Letrozole | 2.5 mg | Tablet | 30's | 090088 | PKR 12,635.59 | PKR 421.19/tablet | Near median |
| Clamycin tabs | Clarithromycin | 250 mg | Tablet | 10's | 072131 | PKR 454.75 | PKR 45.48/tablet | Near median |
| Clamycin tabs | Clarithromycin | 500 mg | Tablet | 10's | 072132 | PKR 821.73 | PKR 82.17/tablet | Near median |
| LithcellSource observed | Lithium carbonate | 400 mg | Tablet | 10x10's | 136753Official source ↗ | No indexed price | — | — |
| Mofloxen tabs | Moxifloxacin | 400 mg | Tablet | 5`s | 075420 | PKR 877.14 | PKR 175.43/tablet | Near median |
| NeoQuel | Quetiapine | 25 mg | Tablet | 30's | 092082 | PKR 631.78 | PKR 21.06/tablet | Near median |
| NeoQuel | Quetiapine | 100 mg | Tablet | 30's | 092083 | PKR 1,438.36 | PKR 47.95/tablet | 36% below median |
| NeoQuel tabs | Quetiapine | 100 mg | Tablet | 10's | 092083 | PKR 678.15 | PKR 67.82/tablet | 9% below median |
| NeoQuel XR | Quetiapine | 150 mg | Extended-release tablet | 30's | 092084 | PKR 1,864.54 | PKR 62.15/tablet | 26% below median |
| NeoQuel XR | Quetiapine | 150 mg | Extended-release tablet | 10's | 092084 | PKR 879.35 | PKR 87.94/tablet | 7% above median |
| NeoQuel XR | Quetiapine | 300 mg | Extended-release tablet | 30's | 092085 | PKR 3,106.46 | PKR 103.55/tablet | 24% below median |
| NeoQuel XR | Quetiapine | 300 mg | Extended-release tablet | 10's | 092085 | PKR 1,464.81 | PKR 146.48/tablet | 7% above median |
| Norani caps | Omeprazole | 20 mg | Capsule | 14's | 072147 | PKR 265.91 | PKR 18.99/capsule | Near median |
| Norani caps | Omeprazole | 20 mg | Capsule | 10's | 072147 | PKR 177.76 | PKR 17.78/capsule | 10% below median |
| Omited | Omeprazole | 40 mg | Capsule | vial | 098343 | PKR 553.98 | PKR 553.98/capsule | 1,498% above median |
| Omited | Omeprazole | 40 mg | Capsule | 1's | 098343 | PKR 553.98 | PKR 553.98/capsule | 1,498% above median |
| Omitid caps | Omeprazole | 40 mg | Capsule | 14's | 072921 | PKR 461.65 | PKR 32.98/capsule | Near median |
| Rani | Ranitidine | 150 mg | Tablet | 10's | 072141 | PKR 103.41 | PKR 10.34/tablet | 7% below median |
| Repdon | Risperidone | 1 mg | Tablet | 10's | 072029 | PKR 221.59 | PKR 22.16/tablet | Near median |
| Repdon | Risperidone | 2 mg | Tablet | 10's | 072030 | PKR 360.09 | PKR 36.01/tablet | Near median |
| Repdon | Risperidone | 3 mg | Tablet | 10's | 072031 | PKR 553.98 | PKR 55.40/tablet | Near median |
| Repdon | Risperidone | 4 mg | Tablet | 10's | 072889 | PKR 720.17 | PKR 72.02/tablet | Near median |
| Si-Lenza tabs | Olanzapine | 5 mg | Tablet | 10's | 077824 | PKR 179.01 | PKR 17.90/tablet | Near median |
| Siflux | Fluoxetine | 20 mg | Capsule | 10's | 072914 | PKR 105.60 | PKR 10.56/capsule | 19% below median |
| Silox tabs | Levofloxacin | 250 mg | Tablet | 10`s | 072139 | PKR 461.65 | PKR 46.17/tablet | Near median |
| Silox tabs | Levofloxacin | 500 mg | Tablet | 10`s | 072140 | PKR 768.18 | PKR 76.82/tablet | Near median |
| Sixime | Cefixime | 400 mg | Capsule | 5's | 086250 | PKR 600.14 | PKR 120.03/capsule | 6% above median |
| Sixime | Cefixime | 100 mg/5 mL | Suspension | 30ml | 086251 | PKR 332.39 | PKR 11.08/mL | 6% above median |
| Sixone | Sterile Ceftrioxone | 1 g | Injection | Vial | 083443 | PKR 623.22 | PKR 623.22/vial/unit | No comparator |
| Sixone | Sterile Ceftrioxone | 500 mg | Injection | Vial | 083444 | PKR 313.93 | PKR 313.93/vial/unit | Near median |
| Sixone | Sterile Ceftrioxone | 250 mg | Injection | Vial | 083445 | PKR 196.09 | PKR 196.09/vial/unit | Near median |
| Sixone | Sterile Ceftrioxone | 250 mg | Injection | Vial | 111820 | PKR 187.08 | PKR 187.08/vial/unit | Near median |
| Sixone | Sterile Ceftrioxone | 500 mg | Injection | Vial | 111821 | PKR 314.88 | PKR 314.88/vial/unit | Near median |
| Strem tabs | Ondansetron | 8 mg | Tablet | 12's | 100708 | PKR 1,959.11 | PKR 163.26/tablet | Near median |
| Strem tabs | Ondansetron | 8 mg | Tablet | 10`s | 100708 | PKR 1,632.58 | PKR 163.26/tablet | Near median |
| Zesin | Azithromycin | 250 mg | Capsule | 6's | 075231 | PKR 282.53 | PKR 47.09/capsule | Near median |
| Zesin | Azithromycin | 500 mg | Capsule | 6's | 075232 | PKR 437.64 | PKR 72.94/capsule | 12% below median |
| Zesin | Azithromycin | 500 mg | Capsule | 3's | 075232 | PKR 230.82 | PKR 76.94/capsule | 7% below median |
| Zesin caps | Azithromycin | 250 mg | Capsule | 10's | 075231 | PKR 470.88 | PKR 47.09/capsule | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.